David Golden, MD

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

Articles by David Golden, MD

Unmet Needs and Challenges in Allergy Management | Credit: HCPLive

Expanding Epinephrine Options to Reduce Barriers, Improve Early Use

ByDavid Golden, MD,Jay Lieberman, MD,Brian Schroer, MD

February 11th 2026

Part 4 highlights how expanding epinephrine delivery options can reduce barriers, support earlier administration, and improve real-world anaphylaxis outcomes.

Recognizing, Managing Anaphylaxis in Infants

ByDavid Golden, MD,Jay Lieberman, MD,Brian Schroer, MD

February 11th 2026

In this segment, experts emphasize the importance of giving an infant experiencing anaphylaxis epinephrine at whatever dose may be available rather than delaying treatment.

Delinking Epinephrine Use From Mandatory ED Visits

ByDavid Golden, MD,Jay Lieberman, MD,Brian Schroer, MD

February 11th 2026

In the second part of the special report, panelists delink epinephrine use from mandatory emergency department visits.

Updated Anaphylaxis Guidelines, Early Management Priorities

ByDavid Golden, MD,Jay Lieberman, MD,Brian Schroer, MD

February 11th 2026

In the opening segment of this special report, panelists discuss updated anaphylaxis guidelines and early management priorities.

David Golden, MD Credit: Aquestive Therapeutics

Potential of Epinephrine Sublingual Film for Anaphylaxis, With David Golden, MD

ByDavid Golden, MD

February 6th 2026

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

Anaphylm Remains Promising for Anaphylaxis Despite FDA CRL, With David Golden, MD

ByDavid Golden, MD

February 3rd 2026

Despite usability concerns cited by the FDA, investigators say dibutepinephrine’s needle-free, portable design could still address gaps in real-world epinephrine use.

Anticipating The FDA Decision of Anaphylm for Anaphylaxis, With David Golden, MD

ByDavid Golden, MD

January 27th 2026

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

HCPLive Five at ACAAI 2025

ByPrincess Ogbogu, MD,David Golden, MD,Amber Luong, MD, PhD,Adil Adatia, MD,Druhan Howell, MD

December 9th 2025

This HCPLive Five features advancements in asthma, immunology, and allergy that were presented at the ACAAI 2025 meeting in Orlando.

Sublingual Epinephrine Film Well Tolerated in Children, With David Golden, MD

ByDavid Golden, MD

November 10th 2025

At ACAAI 2025, Golden discussed how mild local reactions and expected systemic effects support the sublingual film’s strong safety profile in children.

Sublingual Epinephrine Film Rapidly Works in Children, With David Golden, MD

ByDavid Golden, MD

November 9th 2025

Children achieved therapeutic epinephrine levels within 2 minutes on AQST-109 (Anaphylm), showing an early cardiovascular response similar to adults.

HCPLive Five – Allergy Updates at AAAAI 2025

ByDavid Golden, MD,Kent Lam, MD,Robert Wood, MD,Casey Cohen, PhD,Joseph K. Han

March 21st 2025

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key allergy updates from the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI) annual meeting.

When to Test and How to Treat Insect Sting Allergies, with David Golden, MD

ByChelsie Derman,David Golden, MD

March 7th 2025

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

Treating Insect Sting Allergies in Various Populations, with David Golden, MD

ByChelsie Derman,David Golden, MD

March 6th 2025

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.